Novel long-circulating lipid nanocapsules.

Area of Science:

• Nanotechnology
• Drug Delivery Systems
• Materials Science

Background:

• Lipophilic drugs often face challenges in achieving effective tumor delivery due to poor solubility and rapid clearance.
• Developing advanced nanocarrier systems is crucial for enhancing the therapeutic efficacy of such drugs.

Purpose of the Study:

• To create and assess novel long-circulating lipid nanocapsules (LN) specifically engineered for the targeted delivery of lipophilic drugs to tumors.
• To evaluate the pharmacokinetic and biodistribution profiles of these novel nanocapsules in vivo.

Main Methods:

• Lipid nanocapsules were fabricated using a solvent-free phase inversion technique.
• Surface modification was achieved through polyethylene glycol distearoylphosphatidylethanolamine (DSPE-PEG) conjugation, either during preparation or via post-insertion.
• In vivo studies in rats were performed to determine LN pharmacokinetics and biodistribution.

Main Results:

• The post-insertion method proved effective for producing LN with controlled sizes and high surface PEG density.
• PEGylated LN demonstrated prolonged circulation times in vivo, with up to 50% of the injected dose remaining in the blood after 8 hours.
• The area under the blood concentration-time curve for these LN approached 70% of that observed for Doxil liposomes, indicating favorable circulation persistence.

Conclusions:

• A straightforward, solvent-free process enables the production of long-circulating lipid nanocapsules with tunable sizes.
• These developed nanocapsules hold significant promise for the passive targeting and delivery of lipophilic anticancer agents to solid tumors.